Clinical Trial

A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC Deficiency

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated April 21, 2026 (before its estimated July 23, 2026 completion). Its status may not reflect the trial's current state.
Summary
This trial includes dose-escalating part (phase 1) and dose confirming part, to prove the safety and efficacy of VGN-R09b to treat patients with severe AADC deficiency
Protocol Amendment History 1 change
critical Phase changed: Phase 3 -> Phase 2/3 2026-04-22
Trial Details
NCT Number NCT06432140
Lead Sponsor Shanghai Vitalgen BioPharma Co., Ltd.
Conditions Aromatic L-amino Acid Decarboxylase Deficiency
Enrollment 13 participants
Start Date 2024-07-02
Primary Completion 2026-07-23 (estimated)
Study Completion 2030-09-20 (estimated)
Updated on ClinicalTrials.gov 2026-04-21